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hydrotherapy in the management of fibromyalgia
syndrome: a qualitative systematic review and
meta-analysis of randomized controlled trials
Johannes Naumann*† and Catharina Sadaghiani†Abstract
Introduction: In the present systematic review and meta-analysis, we assessed the effectiveness of different forms
of balneotherapy (BT) and hydrotherapy (HT) in the management of fibromyalgia syndrome (FMS).
Methods: A systematic literature search was conducted through April 2013 (Medline via Pubmed, Cochrane Central
Register of Controlled Trials, EMBASE, and CAMBASE). Standardized mean differences (SMDs) and 95% confidence
intervals (CIs) were calculated using a random-effects model.
Results: Meta-analysis showed moderate-to-strong evidence for a small reduction in pain (SMD −0.42; 95% CI
[−0.61, −0.24]; P < 0.00001; I2 = 0%) with regard to HT (8 studies, 462 participants; 3 low-risk studies, 223
participants), and moderate-to-strong evidence for a small improvement in health-related quality of life (HRQOL; 7
studies, 398 participants; 3 low-risk studies, 223 participants) at the end of treatment (SMD −0.40; 95% CI
[−0.62, −0.18]; P = 0.0004; I2 = 15%). No effect was seen at the end of treatment for depressive symptoms and tender
point count (TPC).
BT in mineral/thermal water (5 studies, 177 participants; 3 high-risk and 2 unclear risk studies) showed moderate
evidence for a medium-to-large size reduction in pain and TPC at the end of treatment: SMD −0.84; 95% CI
[−1.36, −0.31]; P = 0.002; I2 = 63% and SMD −0.83; 95% CI [−1.42, −0.24]; P = 0.006; I2 = 71%. After sensitivity analysis,
and excluding one study, the effect size for pain decreased: SMD −0.58; 95% CI [−0.91, −0.26], P = 0.0004; I2 = 0.
Moderate evidence is given for a medium improvement of HRQOL (SMD −0.78; 95% CI [−1.13, −0.43]; P < 0.0001;
I2 = 0%). A significant effect on depressive symptoms was not found. The improvements for pain could be maintained
at follow-up with smaller effects.
Conclusions: High-quality studies with larger sample sizes are needed to confirm the therapeutic benefit of BT and HT,
with focus on long-term results and maintenance of the beneficial effects.Introduction
Fibromyalgia syndrome (FMS) is a debilitating condition of
almost unknown etiology and pathogenesis that is charac-
terized by widespread musculoskeletal pain and tenderness,
as well as secondary symptoms like fatigue, depression, ir-
ritable bowel syndrome and sleep disturbances. A standard* Correspondence: johannes.naumann@uniklinik-freiburg.de
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article, unless otherwise stated.therapy regimen is lacking and the condition causes high
direct and indirect costs (for example, health care use, sick
leave) [1]. In a survey of the German population using the
modified American College of Rheumatology (ACR) 2010
preliminary diagnostic criteria for FMS [2], the overall
prevalence of FMS was found to be 2.1% to 2.4% in women
and 1.8% in men; however, the difference was not statisti-
cally significant [3]. Adequate treatment recommendations
are therefore needed both in the interests of the welfare of
the patient and for economic reasons. Current evidence-
based guidelines are built on the fact that there is no single
ideal treatment for FMS. Patient-tailored approachesMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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pharmacological interventions according to individual
symptoms (for example, pain, sleep problems, fatigue, and
depression). Especially, self-management strategies (for
example, exercise, psychological techniques) involving ac-
tive patient participation should be an integral component
of the therapeutic plan [4].
In this context, balneotherapy (BT) and hydrotherapy
(HT) offer interesting treatment alternatives and are com-
monly used additional interventions in the management of
FMS, despite ongoing debate about their eff ícacy. Prior re-
search (an Internet survey of 2,596 people with FMS)
found that around 26% of individuals suffering from FMS
use pool therapy and 74% heat modalities (warm water, hot
packs). The interventions perceived to be most effective
(effectiveness rating ≥6.0) on a scale of 0 to 10, with 10 be-
ing most effective, were rest, (6.3 ± 2.5) (mean ± SD), heat
modalities (6.3 ± 2.3), pain medication (6.3 ± 2.4), sleep
medication (6.5 ± 2.7) and pool therapy (6.0 ± 3.0) [5].
However, the mechanisms by which immersion in mi-
neral or thermal water or application of mud alleviates the
symptoms of FMS are almost unknown. Pain, the key
symptom of FMS, may be relieved by the hydrostatic pres-
sure and the effects of temperature on the nerve endings,
as well as by muscle relaxation [6]. Furthermore, it has
been shown that thermal mud baths increase plasma
levels of beta-endorphin, thus explaining their analgesic
and antispastic effect, which is particularly important in
patients with FMS [7]. The beneficial effects of water
treatments are probably the result of a combination of
specific (for example, buoyancy, aquatic resistance, heat)
and unspecific effects (for example, change of environ-
ment, spa-scenery).
However, the definitions BT, HT and spa therapy are
frequently confused and the terms tend to be used inter-
changeably [8]. In contrast to HT, which generally em-
ploys normal tap water, BT uses thermal mineral water
from natural springs, but also natural gases (CO2, iodine,
sulfur, radon, et cetera), peloids (mud) and other edaphic
remedies (for example, hay) for medical treatment. BT is
usually practiced in spas with their special therapeutic
atmosphere as part of a complex therapy program,
which is why the term is often used synonymously for
spa therapy. Thalassotherapy is a special form of BT or
spa treatment that uses seawater and the seaside climate.
New definitions, such as health resort medicine, rather
than BT and spa therapy, have not reached general ac-
ceptance [9].
Prior systematic reviews and meta-analyses covering BT
(spa therapy) and HT in FMS have respectively covered
the literature up to May 2011 [6], and December 2008
[10]. The systematic review by Terhorst et al. (2011) [11]
on complementary and alternative medicine analyzed,
among others, 11 studies on BT up to December 2010.The network meta-analysis by Nüesch et al. (2013) [12],
which investigated pharmacological and non-pharmaco-
logical interventions (land- and water-based aerobic exer-
cise, multicomponent treatment (MCT), BT and cognitive
behavioral therapy (CBT)), covered the literature up to
2011. In summary, these reviews found some evidence of
beneficial effects arising from BT and HT, however, due to
methodological flaws, their efficacy remains unclear.
Despite these limitations, German and Israeli guidelines
recommend temporary use of BT and HT (grade B/C)
[13,14]. Furthermore, BT and HT are often part of MCT
(at least one exercise and one psychological component)
but they are not analyzed separately. In several evidenced-
based guidelines and reviews, MCT and aerobic exercises
(land-based or water-based) are strongly recommended
[12-15]. The aim of the present review is to offer an up-
date of the literature on BT and HT in FMS, with special
focus on separate analyses of the different treatment
modalities.
Methods
This systematic review was performed according to the
statement, preferred reporting items for systematic re-
views and meta-analyses (PRISMA) [16] and the recom-
mendations of the Cochrane Collaboration [17].
Literature search
Electronic bibliographic databases (Medline via Pubmed,
Cochrane Central Register of Controlled Trials, EMBASE,
and CAMBASE) were screened up to April 2013. The
search strategy was constructed around a broad range of
balneotherapeutic and hydrotherapeutic treatments: BT,
HT, thalassotherapy, spa therapy, cryotherapy, thermo-
therapy, and phytothermotherapy combined with FMS.
The search filter was restricted to randomized controlled
trials (RCTs). Reference lists of relevant articles and re-
views were examined for additional studies.
The search strategy for Pubmed was as follows: (“FMS”
OR “fibromyal*”) AND “RCT” AND (“BT” OR “HT” OR
“thalassotherapy” OR “spa therapy” OR “thermotherapy”
OR “phytothermotherapy” OR “aquatic” OR “hydrogal-
vanic” OR “cryo” OR “pool exercise” OR “water-based” OR
“pool-based” OR “stanger” OR “mud” OR “thermal water”
OR “bath” OR “peloid” OR “natural therapeutic gas” OR
“radon”). The search strategy applied a combination of
text and keywords (medical subject heading (MeSH)
terms) and was adapted for each database if necessary.
Inclusion and exclusion criteria
The criteria were as follows: 1) types of study: RCTs were
only eligible if they were published as full paper articles.
No language restrictions were made; 2) types of partici-
pants: patients of any age diagnosed with FMS on recog-
nized criteria were included; 3) types of intervention:
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water, spa treatment, thalassotherapy, thermotherapy,
peloids, natural therapeutic gas) or HT (treatment in
plain water with or without exercise) with no treatment
or any active treatment. Studies were excluded if BT/
HT treatments were not the main intervention or if the
intervention in treatment and control group were the
same and only the co-therapies differed; and 4) types of
outcome: studies assessing at least one symptom-
specific outcome of the major FMS symptoms [18], such
as pain (for example, tender point count (TPC), visual
analog scale (VAS)), fatigue, sleep disturbances, depres-
sive symptoms, health-related quality of life (HRQOL)
and/or relevant pain-related psychological issues such
as self-efficacy pain and/or objective tests of physical fit-
ness, were included.
Data extraction
The authors (JN, CS) of the review presented here in-
dependently extracted relevant study information (for
example, participants, characteristics of the intervention
and control, outcome measures, results) using pre-
defined data fields, including risk-of-bias indicators. If
necessary, existing inconsistencies were solved by dis-
cussion, and consensus achieved. For quantitative ana-
lysis the mean post-test values, or change scores when
available, were used.
Risk of bias assessment
The risk of bias for each study was determined inde-
pendently by the same two authors (assessment of infor-
mation in study reports) using the criteria of the
Cochrane risk-of-bias tool. Disagreements were resolved
by discussion to achieve consensus.
Summary assessment of risk-of-bias key domains (se-
lection, performance, detection, attrition and reporting
bias), was based on the three-tiered rating style as pro-
posed by Higgins et al. [19]. Performance bias was not
considered a key domain due to the required participa-
tory nature of BT and HT. Studies with a high risk of
bias in one of the key domains or unclear risk in at least
two key domains were considered to be at high risk of
bias. Studies with unclear risk in one of the key domains
were considered to have unclear risk of bias. Only stu-
dies with low risk of bias in all key domains were graded
as having low risk of bias. Analysis was done with the
Review Manager (RevMan) version 5.2 risk-of-bias tool
from the Cochrane Collaboration [21].
Missing data
In the case of reported median, low and high end of
range and sample size only, we estimated the mean and
variance using the appropriate formula as mentioned by
Hozo et al. [20].Data analysis and assessment of heterogeneity
RevMan version 5.2 [21] was used to analyze the data and
perform testing of heterogeneity, using the I2 statistic,
with the following categories: I2 = 25%, no heterogeneity;
I2 = 50%, moderate heterogeneity; I2 = 75%, strong hetero-
geneity [22], and P ≤0.1 for the Chi2 test showing sig-
nificant heterogeneity. We used Cohen’s categories to
evaluate the magnitude of the effect size, calculated by
standardized mean difference (SMD), with g >0.2 to 0.5,
small effect size; g >0.5 to 0.8, medium effect size; and
g >0.8, large effect size. We used the following modified
levels of evidence descriptors to classify the results: (1)
strong, if there were consistent findings among multiple
(≥3) RCTs with low risk of bias; (2) moderate, if there
were consistent findings among multiple high-risk RCTs
and/or one low-risk RCT; (3) limited, with one high-risk
RCT; (4) conflicting, with inconsistent findings among
multiple RCTs; and (5) no evidence, no RCTs [23]. When-
ever possible we used the results from intention-to-treat
analysis. Negative SMDs indicate a beneficial effect of the
experimental intervention.
Subgroup and sensitivity analysis
Where at least two studies were available, subgroup ana-
lyses were pre-specified for different types of intervention.
Additionally, control groups were compared (no treat-
ment/active treatment). Waiting list or treatment-as-usual
were classified as non-intervention control. The subgroup
analyses were also used to examine potential sources of
heterogeneity. Sensitivity analyses were performed for
studies with high versus low risk of bias, respectively, for
studies with serious flaws in one or more key domains
and for sample size per treatment arm.
Results
Literature search
The literature search revealed 107 citations in accordance
with the predefined search terms “FMS” and “BT” or
“HT” and “RCT”. One additional study each was found in
the reference lists of published reviews and the reference
list of an already identified study: 52 duplicates were re-
moved. A further 20 records were excluded because they
did not fulfill the inclusion criteria (no papers on FMS
and/or BT/HT (n = 7) [24-30]; different outcome measure
(cost-effectiveness) (n = 2) [31,32]; reviews [33,34] (n = 2);
no control group [35-38] (n = 4); not randomized [39-42]
(n = 4); HT not the main treatment [43] (n = 1)).
Of the 37 articles that were assessed, four were ex-
cluded because of insufficient data reporting [7,44-46]. A
further three studies were excluded because the main
treatment (BT/HT) was the same both in the treatment
and control group (Altan et al. [47]: baths in mineral
water with and without exercise; Ammer and Melnizky
[48]: whirl baths with and without etheric oils; Calandre
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The remaining 30 articles included 2 reporting follow-
up data to already included studies [50,51], and a further
4 reporting on the same study publication but with dif-
ferent outcome measures [52-55].
Finally, 24 studies met our inclusion criteria and were
included in the qualitative analysis. Of these, 12 reported
on HT [56-67] and 12 on BT [68-79]: 21 studies were
suitable for quantitative analysis, 11 of which reported
on HT and 10 on BT. Three studies had to be excluded
from the quantitative analysis due to insufficient data
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Figure 1 Flowchart of the results of the literature search. BT, balneothDescription of included trials
The characteristics of the included studies are detailed in
the following tables (see Additional files 1 and 2). The
studies were separated according to treatment modalities:
Additional file 1: HT with the subgroups, HT with exer-
cise (n = 10) and hydrogalvanic (Stanger) bath (n = 2).
Additional file 2: BT with the subgroups mineral water
(n = 3), spa therapy (n = 3), sulfur bath (n = 2),
thalassotherapy (n = 1), phytothermotherapy (n = 1), mud
(n = 1), acratothermal water (n = 1). Study characteristics
for all trials included in qualitative synthesis are sum-
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erapy; HT, hydrotherapy; FMS, fibromyalgia syndrome.
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Participants’ age across the studies ranged from 18 to 73
years. The median of the mean age in the treatment group
was 45.2 years compared to 46.3 years in the control
group. Disease duration was reported in 19 studies and
ranged from 1.3 to 24.0 years. The median of mean disease
duration was 8.4 years. Over 96% of the participants
were women. Sixteen studies involved women only
[56,57,62-71,73,75-77], and eight studies included
both women and men [58-61,72,74,78,79]. The me-
dian of the mean pain baseline values reported in 20
studies was 7.1 (5.5 to 9.1). Pain scores were assessed




Two RCTs originated from Canada [59,60], eight from
Turkey [57,58,69,71,72,75,77,78], two from Brazil [56,68],
one from Israel (Dead sea) [70], two from Italy [73,74],
one from Austria [61], three from Spain [62,66,67], one
from Norway [63], two from Sweden [64,65], one from
Germany [76] and one from The Netherlands [79].
Setting
Eighteen studies were conducted in outpatient settings
[56,58-69,72-74,76,78] and six in inpatient settings
[57,70,71,75,77,79]. Seven studies were conducted
within spa resorts either with in-patients or outpatients
[69-71,73,74,77,79]. Patients were referred from pri-
mary, secondary and tertiary care settings.
Inclusion and exclusion criteria
In all the studies, FMS was diagnosed according to the
ACR criteria [80]. Patients with severe diseases were ex-
cluded in 18 studies [56-58,60,62-69,72-76,79] and pa-
tients with mental disorders and/or on antidepressant
drugs in 11 studies [57,58,60,62,64-67,72,75,76]; 6 stu-
dies didn’t report exclusion criteria [59,61,70,71,77,78].
Reporting of adverse events
Adverse events were reported in four studies [56,65,68,79].
In all cases the adverse events were not indicated as
a cause of interruption or dropouts. Seven studies
[57,58,72-75,78] clearly reported that there were no ad-
verse events. The remaining 13 studies gave no informa-
tion on adverse events. No serious adverse events were
reported (for details see Additional files 1 and 2).
Intervention characteristics
HT interventions used, among others, hydrogalvanic/
Stanger bath in two studies [57,61] and exercises in plain
water [56,58-60,62-67]. BT interventions were spa therapy
[71,77,79], thalassotherapy [68], phytothermotherapy [73],mud [74], sulfur bath [70,76], baths in mineral/thermal
water [69,72,78] and in acratothermal water [75]. Treat-
ment duration in the HT group ranged from 5.0 to 32.0
weeks, with a median of 15.5 weeks, in contrast to BT
studies with shorter duration ranging from 1.5 to 12.0
weeks and a median of 2.0 weeks. Median follow-up du-
ration was similar for both HT and BT at 2.5 and 3.5
months respectively.
Outcome measures
Different VAS were used to measure pain. Four studies
did not report how pain was measured [57,73,74,76].
Twenty studies used the Fibromyalgia Impact Ques-
tionnaire (FIQ) to measure HRQOL. Nine studies
[56,58,60,68,69,71,72,75,79] measured depressed mood
by the Beck Depression Inventory (BDI).
Risk of bias
Only 5 of the 24 studies included had low risk of bias
[56,57,64,67,68]; a further 5 were assigned as having un-
clear risk (studies with one unclear judgement; unclear
allocation: [65,71,77]; selective reporting: [66]; unclear
outcome assessment blinding: [79]). The remaining 14
studies were at high risk of bias, as they had two or
more unclear judgements in the key domains, including
5 studies with serious flaws in one or more key domains
[59,60,63,75,76]. For details see categorization of risk of
bias at the individual study level (see Additional file 3).
Sequence generation and treatment allocation
Of 24 studies, 10 had unclear risk of selection bias in
both domains, 2 were considered to be at high risk be-
cause of serious randomization flaws [59,75]. Half the
studies reported adequate randomization, but only seven
adequate allocation concealment [4,6,21,47,52,69,80].
Similar baseline
All studies had low risk of selection bias with the excep-
tion of two, one with unclear risk (unclear reporting;
[76]) and one with high risk due to significant diffe-
rences in baseline characteristics in a major FMS symp-
tom (TPC) [63]).
Blinding of participants and personnel
Performance bias was not considered a key domain. Due
to the participatory nature of BT and HT blinding is not
feasible.
Incomplete outcome data
Of the 24 studies, 19 were assigned low risk of attrition
bias (criteria: attrition rate reported, not exceeding 20%
or intention-to-treat analysis). Five studies were assigned
unclear or high risk of bias because two had high
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rate was not clearly reported in three studies [70,76,78].
Selective reporting
Two studies were assigned high risk of bias [59,75]; thus,
reporting was insufficient and not in alignment with the
values presented in tables. A further five had unclear risk
of reporting bias due either to double reporting [66,70] or
incomplete/inconsistent outcome reporting [60,61,63].
Blinding of outcome assessment
Fifteen of the 24 studies had low risk of detection
bias for outcome assessment, eight had unclear risk
[58,59,61,62,69,72,75,79], and one was assigned a high
risk of bias [76] (see Additional file 4).
Subgroup analyses
Hydrotherapy
Meta-analyses showed moderate-to-strong evidence (con-
sistent findings among multiple (≥3) RCTs with low risk
of bias) for a small reduction in pain with exercises (pool-
based exercise (PBE) in plain water (HT) at the end of
treatment; SMD −0.42; 95% CI −0.61, −0.24; P <0.00001;
I2 = 0% (eight studies: three low-risk studies [56,64,67],
two unclear-risk studies [65,66], three high-risk studies
[58,62,63]). Concerning HRQOL (FIQ) at the end of
treatment, there was moderate-to-strong evidence for a
small improvement; SMD −0.40; 95% CI −0.62, −0.18;
P = 0.0004; I2 = 15% (seven studies: three low-risk studies
[56,64,67], two unclear-risk studies [65,66], two high-risk
studies [60,62]). For depressive symptoms (BDI) and TPC
no significant effect was seen at the end of treatment
(BDI: SMD −0.19; 95% CI −0.88, 0.50; P = 0.59; I2 = 60%
(one low-risk [56] and one high-risk study [60]); TPC:
SMD −0.37; 95% CI −1.12, 0.38; P = 0.33; I2 = 79% (one
unclear risk [66] and two high-risk studies [58,60]) (see
Figure 2).
Comparison group
Subgroup analysis of the type of comparison group sug-
gests that RCTs comparing HT to no treatment (usual
care) or other types of active control had a significant
effect, but not when compared to land-based exercise
(see Additional file 5).
Balneotherapy
Meta-analyses showed moderate evidence for a large re-
duction of pain at the end of treatment with BT in min-
eral/thermal water, regardless of whether within a spa
center (SPA) or not: SMD −0.84; 95% CI −1.36, −0.31;
P = 0.002; I2 = 63% (five studies: two unclear-risk studies
[71,77] and three high-risk studies [69,72,78]). Moderate
evidence was seen for a medium improvement in HRQOL
(FIQ); SMD −0.78; 95% CI −1.13, −0.43; P <0.0001;I2 = 0% (four studies: two unclear-risk [71,77] and two
high-risk studies [69,72]). Moderate evidence for a
large improvement was seen for TPC: SMD −0.83; 95%
CI −1.42, −0.24; P = 0.006; I2 = 71% (five studies: two
unclear-risk [71,77] and three high-risk studies [69,72,78]).
There was no significant effect on depressive symptoms
(BDI) at the end of treatment (SMD −0.87 −1.82, 0.08;
P = 0.07; I2 = 85% (four studies: two unclear-risk [71,77]
and two high-risk studies [69,72]) (see Figure 3).Follow up
Findings at follow up showed that a small reduction of
pain was maintained for HT and BT: SMD −0.25; 95%
CI −0.50, −0.01; P = 0.04; I2 = 0% for HT and SMD −0.30;
95% CI −0.53, −0.07; P = 0.01; I2 = 0% for BT. Only BT
showed significant results for HRQOL (FIQ) (SMD −0.35;
95% CI −0.61, −0.10; P = 0.006; I2 = 0%). With regard to
TPC and BDI, only BT studies provided follow-up data
with SMD −0.39; 95% CI −0.73, −0.05; P = 0.03; I2 = 35%
for TPC and SMD −0.31; 95% CI −0.59, −0.03; P = 0.03;
I2 = 0% for BDI (see Figure 4).Analysis of overall effects
Taking into account all available studies, regardless of
treatment modality, meta-analysis provided moderate
evidence for a medium reduction of pain at the end of
treatment; SMD −0.57; 95% CI −0.77, −0.38; P <0.00001;
I2 = 45%. Results are shown for HT, BT and diverse
treatments: hydrogalvanic bath (Stanger), mud therapy,
sulfur bath and thalassotherapy (see Additional file 6).Sensitivity analyses
Sensitivity analysis according to potential risks of bias
showed no significant difference between the effect size
of pain (HT) at the end of treatment and risk of bias
(see Additional file 7). Analysis according to sample size
(<25, >25) shows a slightly larger effect size and broader
CIs in small studies (P = 0.54) (see Additional file 8).
Statistical heterogeneity of analysis for the effect size
of pain in the BT group (I2 = 63%) was substantially de-
creased (I2 = 0%) by removing the study of Ardiç et al.
[69] (pharmacological co-therapies not allowed; non-
intervention control group). The magnitude of the effect
size was decreased to SMD −0.58; 95% CI −0.91, −0.26,
P = 0.0004, corresponding to a medium effect.Publication bias
Visual analysis of the funnel plot shows a symmetric pic-
ture, with one outlier study already identified by sensi-
tivity analysis [69]. This indicates that the results of the
meta-analysis can be regarded as robust against potential
reporting bias (see Additional file 9).
Pain (VAS 0-10; 0-100) final treatment
Health-related quality of life (FIQ) final treatment
Tender Point Count final treatment
Depressive Symptoms (BDI) final treatment
Study or Subgroup
Assis 2006 HT PBE
Evcik 2008 HT PBE
Gusi 2006 HT PBE
Jentoft 2001 HT PBE
Mannerkorpi 2000 HT PBE+E
Mannerkorpi 2009 HT PBE+E
Munguia 2007 HT PBE
Tomas-Carus 2008 HT PBE
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 6.54, df = 7 (P = 0.48); I² = 0%













































































Experimental Control Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours [experimental] Favours [control]
Study or Subgroup
Assis 2006 HT PBE
Gowans 2001 HT PBE
Gusi 2006 HT PBE
Mannerkorpi 2000 HT PBE+E
Mannerkorpi 2009 HT PBE+E
Munguia 2007 HT PBE
Tomas-Carus 2008 HT PBE
Total (95% CI)
Heterogeneity: Tau² = 0.01; Chi² = 7.06, df = 6 (P = 0.31); I² = 15%





































































Experimental Control Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours [experimental] Favours [control]
Study or Subgroup
Evcik 2008 HT PBE
Gowans 2001 HT PBE
Munguia 2007 HT PBE
Total (95% CI)
Heterogeneity: Tau² = 0.35; Chi² = 9.59, df = 2 (P = 0.008); I² = 79%





































Experimental Control Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours [experimental] Favours [control]
Study or Subgroup
Assis 2006 HT PBE
Gowans 2001 HT PBE
Total (95% CI)
Heterogeneity: Tau² = 0.15; Chi² = 2.49, df = 1 (P = 0.11); I² = 60%





























Experimental Control Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours [experimental] Favours [control]
Figure 2 Treatment effects of exercises in plain water (hydrotherapy, HT) at the end of treatment. PBE, pool-based exercise; +E, plus
education; VAS, visual analog scale; FIQ, fibromyalgia impact questionnaire; BDI, Beck depression inventory.
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Figure 3 Treatment effects of balneotherapy (BT) in mineral/thermal water (MW), within a spa center (SPA) or not, at the end of
treatment. VAS, visual analog scale; FIQ, fibromyalgia impact questionnaire; BDI, Beck depression inventory.
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Figure 4 Treatment effect of hydrotherapy (HT)/balneotherapy (BT) at follow up. VAS, visual analog scale; FIQ, fibromyalgia impact
questionnaire; BDI, Beck depression inventory.
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Summary of evidence
The primary aim of this systematic review and meta-
analysis was to determine the therapeutic benefit of BT
and HT in the management of FMS, with special focus on
separate analyses of the different treatment modalities. For
HT with exercise we found moderate-to-strong evidence
(consistent findings among ≥3 RCTs with low risk of bias)
for a small improvement in pain (eight studies, 462 partic-
ipants; including three low-risk studies, 223 participants)
and HRQOL (seven studies, 398 participants; including
three low-risk studies, 223 participants). Follow-up data
provided moderate evidence (consistent findings among
multiple high-risk RCTs and/or one low-risk RCT) for
maintenance of improvement, at least with regard to pain
(four studies, 254 participants; including one low-risk
study, 125 participants). However, no evidence was found
for improvement of depressive symptoms (BDI) and TPC.
Furthermore, no group difference was found when
comparing water-based exercise to land-based exercise.
This is in accordance with the review by Häuser et al.
from 2010 [81].
We found moderate evidence of a medium-to-large
effect on pain and TPC for BT with mineral/thermal water
(five studies, 177 participants; including three high-risk
and two unclear-risk studies), a medium effect on HRQOL,
and no significant effect on depressive symptoms (BDI).
Moderate evidence for maintenance of these improve-
ments was found at follow up. However, the effects were
smaller. The results confirm the conclusions of other re-
views on BT [6,82].
Besides these two larger groups, further subgroup ana-
lyses were not possible due to the limited number of
available studies and/or provided data. This is also true
of the follow-up data provided, where only a few studies
remained for statistical analyses. The evidence on the
long-term effects that can be concluded from this meta-
analysis is limited.
No conclusions can be drawn on hydrogalvanic/Stanger
baths, thalassotherapy, mud baths, phytothermotherapy or
sulfur baths, which were only represented by one study
each. So as not to lose the information provided by these
studies, we pooled all the available studies in an overall
analysis, which showed similar effects (reduction of pain)
to HT or BT.
Concerning safety, only preliminary conclusions can be
drawn, because reporting of adverse events and the rea-
sons for dropouts was poor. The data suggest that HT and
BT are safe and well-accepted treatments, which is in line
with other recommendations [10,83], and we should not
forget the daily experience of patients and the general
population practising some kind of BT or HT.
Male participants were rarely included in the study
populations, and separate gender comparisons were notreported. Evidence for treatment effects in the manage-
ment of FMS in men is limited. Furthermore, it has to
be taken into account that the population of FMS pa-
tients participating in a trial is selected. Generalisability
may be restricted [84].
Limitations
As so often in evidence-based approaches to non-
pharmacological modalities, limitations are inherent and
inevitable. This is especially true for BT, which depends
on local conditions such as climate or water composition
and provides a large variety of treatment modalities. Ab-
sence of blinding is also inevitable wherever treatment
requires active participation on the part of the study
subjects and clinicians.
There are also several methodological limitations. The
analyses were underpowered due to the small number of
studies and patients included. Analysis according to
sample size (<25, >25) showed a slightly larger effect size
and broader CIs in small studies (P = 0.54). The me-
thodological quality (risk of bias) of the included studies
varied, and was slightly better in HT studies than BT
studies. Although some studies had low risk of bias, the
majority - especially older studies - were associated with
unclear or high risk of bias. Nevertheless, sensitivity ana-
lyses could show, at least in HT studies, that the effect
sizes were not affected by methodological bias. Due to
the limited number of BT studies, sensitivity analyses
could not be performed here. Furthermore, the sample
sizes in the BT studies were very small (<25 per treat-
ment arm), except for one study [79]. Unfortunately, in
this study, no results were collected for the control
group after treatment. Thus, the data were not analyzed
and only follow-up data were used.
Heterogeneity was not present in the HT studies, in
contrast to considerable heterogeneity in the BT studies.
This could be explained by the fact that co-therapies
were not allowed in one study, which also had a non-
interventional control group [69]. As far as selection bias
is concerned, it is not possible to assess the extent to
which the results may be influenced. Most of the studies
reported unclear randomization methods as well as
insufficient allocation concealment. The studies that
allowed co-therapies did not control their effects for
dosage or changes in concomitant therapies.
A strength of this review is the homogenous pool of
treatment approaches selected for subgroup analyses,
based on the professional expertise in the field of balne-
ology of one of the authors (JN). The evidence of the
integrated effect sizes seems robust, especially since pub-
lication bias is not plausible after visual analysis of the
funnel plot, showing a symmetric picture, except for one
outlier study [69] already identified by sensitivity ana-
lysis. Commencing from a systematic and thorough
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Conclusions
In summary, based on the limited number of studies
analyzed, small sample sizes and risk of bias attributed
to the studies, it appears difficult to determine the over-
all benefit of BT and HT. There is a risk of overestima-
ting the evidence on the efficacy of HT and even more
so BT. However, although evidence is limited, recom-
mendations in recent evidence-based interdisciplinary
guidelines emphasize a patient-tailored approach with
aerobic exercises, CBT and MCT according to the key
symptoms of FMS [4]. In this context, BT and HT offer
a wide variety of treatment opportunities, which can be
perfectly adapted to the patients’ abilities and prefe-
rences. Unlike pharmacological treatments with ques-
tionable clinical relevance and frequent side effects [12],
the results of this review underline the potential value of
BT and HT as supplementary therapy in the manage-
ment of major symptoms of FMS.
In order to provide a better database for meta-analyses
(internal validity), the use of a core set of outcome mea-
sures (outcome measures in rheumatology (OMERACT)
[85]) including response rates is desirable. Future authors
should use the consolidated standards of reporting trials
(CONSORT) checklist [86] to report study results. Major
interest should focus on long-term results and mainten-
ance of beneficial effects. Given the popularity of BT and
HT among patients with FMS, further studies with robust
methodology are warranted to demonstrate and confirm
the therapeutic benefits.
Additional files
Additional file 1: Table S1. Hydrotherapy - characteristics of the included
studies. Hydrotherapy with the subgroups, hydrotherapy (HT) with exercise
(n = 10) and hydrogalvanic (Stanger) bath (n = 2). Detailed study characteristics:
author, year, risk of bias (high, unclear, low), intent-to-treat analysis (yes/no),
sample size (treatment group/control group), sex, mean age, fibromyalgia
syndrome (FMS) (duration/years), pain (visual analog scale, VAS), dropouts
(n), treatment (treatment group/control group), co-therapies, outcome
measures (primary/secondary outcome), treatment efficacy and safety
(adverse effects).
Additional file 2: Table S2. Balneotherapy - characteristics of the included
studies. Balneotherapy with the subgroups, mineral water (n = 3), spa therapy
(n = 3), sulfur bath (n = 2), thalassotherapy (n = 1), phytothermotherapy
(n = 1), mud (n = 1), acratothermal water (n = 1). Detailed study characteristics:
author, year, risk of bias (high, unclear, low), intent-to-treat analysis (yes/no),
sample size (treatment group/control group), sex, mean age, fibromyalgia
syndrome (FMS) (duration/years), pain (visual analog scale, VAS), dropouts (n),
treatment (treatment group/control group), co-therapies, outcome measures
(primary/secondary outcome), treatment efficacy and safety (adverse effects).
Additional file 3: Risk of bias summary. The file contains authors’
judgements about each risk-of-bias item for each included study. Risk of
bias: high, unclear, low. Items: selection bias (random sequence generation,
allocation concealment, similar baseline characteristics); performance bias
(blinding of participants and personnel); attrition bias (incomplete outcomedata); reporting bias (selective reporting); detection bias (blinding of out-
come assessment). BT, balneotherapy; HT, hydrotherapy; MW, mineral water;
PBE, pool-based exercise; SB, sulfur bath; TT, thalassotherapy; Spa, spa center;
Stanger, Stanger bath; Mud, mud bath; Hay, phytothermotherapy; PBE + E,
pool-based exercise + education; PTM, physical therapy modalities
(transcutaneous electrical nerve stimulation (TENS), ultrasound, infrared).
Additional file 4: Risk of bias graph. The file contains authors’
judgement of each risk of bias item presented as percentages across all
included studies.
Additional file 5: Subgroup analysis for control group (LBE = land-
based exercise; PBE = pool-based exercise; +E = education). The file
contains the subgroup analysis regarding type of comparison group.
Additional file 6: Treatment effect of hydrotherapy (HT),
balneotherapy (BT) and diverse therapies (hydrogalvanic bath
(Stanger), mud therapy, sulfur bath (SB) and thalassotherapy (TT)
on pain. The file contains the analysis of overall effects, taking into
account all available studies, regardless of treatment modality.
Additional file 7: Sensitivity analysis for risk of bias (hydrotherapy
(HT), pain). The file contains the forest plot displaying the relationship
between effect size and risk of bias.
Additional file 8: Sensitivity analysis for sample size (hydrotherapy
(HT), pain). The file contains the forest plot displaying the relationship
between effect size and sample size.
Additional file 9: Funnel plot (based on data of overall analysis,
n = 17 studies). The file contains the scatter plot of the intervention
effect estimates (SMD) from individual studies against their standard
errors (SE). Publication bias may lead to asymmetry in funnel plots on
visual inspection.
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